神经精神性系统性红斑狼疮的治疗策略与结局:一项国际多中心回顾性研究
该回顾性队列研究纳入350例次首次神经精神(NP)事件,按美国风湿病学会分类分为中枢弥漫型、中枢局灶型和外周型。12个月随访时64%患者NP表现临床改善,临床判断归因于SLE并接受免疫抑制剂治疗者临床应答概率显著更高(OR 2.55,95%CI 1.06-6.41,P=0.04)。
要点
- 12个月随访时64%患者NP表现临床改善。
- 临床判断归因于SLE并接受免疫抑制剂治疗者临床应答概率更高(OR 2.55,95%CI 1.06-6.41,P=0.04)。
- 中枢局灶型事件与诊断时年龄为额外的应答预测因素。
核心结论
- 临床判断归因于SLE并接受免疫抑制剂治疗的NP表现,12个月结局改善。
- 这强调了准确归因和及时诊断NPSLE的重要性。
研究设计与样本
- 国际多中心回顾性队列研究,纳入350例次首次NP事件。
- NP事件按美国风湿病学会病例定义分为中枢弥漫型、中枢局灶型和外周型三组。
- 采用临床判断和验证过的归因算法进行NP事件归因。
- 临床结局由医师采用七点Likert量表判定。
- 采用多因素logistic回归分析临床改善/缓解的预测因素。
主要发现
- 免疫抑制剂和糖皮质激素更常用于SLE归因的中枢弥漫型或局灶型NP表现。
- 12个月随访时64%患者NP表现临床改善。
- 中枢局灶型事件和SLE归因表现与更高的临床改善率相关。
- 临床判断归因于SLE并接受免疫抑制剂治疗者临床应答概率显著更高(OR 2.55,95%CI 1.06-6.41,P=0.04)。
- 诊断时年龄和中枢局灶型事件为额外的应答预测因素。
关键数值与推荐
- NP事件按美国风湿病学会病例定义分类为中枢弥漫型、中枢局灶型和外周型。
- 临床结局采用医师七点Likert量表判定。
- 临床判断归因于SLE并接受免疫抑制剂治疗者临床应答的OR为2.55(95%CI 1.06-6.41,P=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The management of neuropsychiatric systemic lupus erythematosus (NPSLE) poses considerable challenges due to limited clinical trials. Therapeutic decisions are customized based on suspected pathogenic mechanisms and symptoms severity. This study aimed to investigate therapeutic strategies and disease outcome for patients with NPSLE experiencing their first neuropsychiatric (NP) manifestation. METHODS: This retrospective cohort study defined NP events according to the American College of Rheumatology case definition, categorizing them into three clusters: central/diffuse, central/focal and peripheral. Clinical judgment and a validated attribution algorithm were used for NP event attribution. Data included demographic variables, SLE disease activity index, cumulative organ damage, and NP manifestation treatments. The clinical outcome of all NP events was determined by a physician seven-point Likert scale. Predictors of clinical improvement/resolution were investigated in a multivariable logistic regression analysis. RESULTS: The analysis included 350 events. Immunosuppressants and corticosteroids were more frequently initiated/escalated for SLE-attributed central diffuse or focal NP manifestations. At 12 months of follow-up, 64% of patients showed a clinical improvement in NP manifestations. Focal central events and SLE-attributed manifestations correlated with higher rates of clinical improvement. Patients with NP manifestations attributed to SLE according to clinical judgment and treated with immunosuppressants had a significantly higher probability of achieving clinical response (OR 2.55, 95%CI 1.06-6.41, P = 0.04). Age at diagnosis and focal central events emerged as additional response predictors. CONCLUSION: NP manifestations attributed to SLE by clinical judgment and treated with immunosuppressants demonstrated improved 12-month outcomes. This underscores the importance of accurate attribution and timely diagnosis of NPSLE.
引用
- Bortoluzzi A, Fanouriakis A, Silvagni E, et al. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study. Rheumatology (Oxford). 2024. PMID: 38402539. doi:10.1093/rheumatology/keae119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。